Humanin

Humanin is a short peptide made from a small, overlooked gene inside mitochondrial DNA rather than the cell’s main genome. First described in 2001, it protects cells from dying under stress in laboratory and animal studies and has become a focus of “mitochondrial-derived peptide” research into aging, metabolism, and neurodegeneration. It has not been tested in registered human clinical trials, and no dosage has been established for human use.

Research snapshot

Peptide category	Mitochondrial-derived peptide (MDP), encoded within mitochondrial DNA rather than the nuclear genome
Primary research interest	Cytoprotection under cellular stress; aging, metabolism, and neurodegeneration research
Highest available evidence	Tier 3/4 — laboratory and animal studies; first described in 2001
Human research available	No — has not been tested in registered human clinical trials
Development status	Preclinical research compound; no company has publicly disclosed an active human clinical trial program for Humanin or its analogs
Regulatory status	No approved medical use anywhere; not FDA- or EMA-approved; not a registered dietary supplement ingredient; sold labeled for research use only

Technical identity

Primary name	Humanin (HN)
Alternative names	Mitochondrial-derived peptide (MDP); various synthetic analogs (e.g. HNG, HNGF6A) referenced in the research literature
Peptide sequence	Not independently re-verified in this pass — a 24-amino-acid peptide encoded within a region of the mitochondrial 16S ribosomal RNA gene
Amino-acid length	24
Molecular formula	Not independently re-verified in this pass
Molecular weight	Not independently re-verified in this pass
CAS Registry Number	Not independently re-verified in this pass
PubChem CID	Not independently re-verified in this pass
Peptide class	Mitochondrial-derived peptide
Primary biological target	Multiple proposed targets across studies, including interaction with the pro-apoptotic protein Bax and various cell-surface receptors implicated in cytoprotective signaling
Developer or originator	Independently discovered by three research groups around 2001, including the Nishimoto laboratory (which named it “Humanin”) screening for factors protecting neurons from amyloid-beta toxicity
Development status	Preclinical; not in disclosed human drug development

What it is

Humanin is a 24-amino-acid peptide encoded within the mitochondrial genome, inside a region of the 16S ribosomal RNA gene rather than a conventional protein-coding gene. It was independently discovered by three research groups around 2001: one screening for factors that protect neurons from amyloid-beta toxicity in Alzheimer’s disease research (the Nishimoto laboratory, which named it “Humanin”), one screening for proteins that interact with the pro-apoptotic protein Bax (the Reed laboratory), and one screening for proteins that bind insulin-like growth factor binding protein 3, or IGFBP3 (the Cohen laboratory).

Humanin belongs to a small family of “mitochondrial-derived peptides” that also includes MOTS-c and the SHLP (small humanin-like peptide) series. These are natural signaling molecules the body already produces at low levels, not synthetic drugs, though the material sold online as “Humanin peptide” is manufactured synthetically to match the natural sequence, or to match modified variants such as HNG.

Research interest centers on Humanin’s apparent ability to protect cells, particularly neurons, cardiac cells, and pancreatic beta cells, from stress and programmed cell death. It circulates in blood, and levels appear to decline with age in several human observational studies, which is part of why it is discussed in longevity research. It remains an experimental research compound. No pharmaceutical company has advanced Humanin itself, or a direct analog, into registered human clinical trials as of this review, and it has no approved medical use.

How does it work?

Plain-English explanation

Cells have a built-in “self-destruct” program (called apoptosis) that activates when they are badly damaged or stressed. Humanin appears to interfere with the early steps of that self-destruct signal, giving stressed cells a chance to survive rather than die. It also appears to help cells clean up damaged internal components (a process called autophagy) and to dampen inflammatory signaling. Because it comes from mitochondria, the cell’s energy-producing structures, researchers view it as part of a communication system mitochondria use to tell the rest of the cell how stressed they are.

Technical explanation

Humanin acts through both intracellular and extracellular routes. Intracellularly, it has been reported to bind and neutralize pro-apoptotic proteins including Bax and truncated Bid (tBID), and to interact with IGFBP3 and the E3 ubiquitin ligase TRIM11. Extracellularly, it engages a tripartite cell-surface receptor complex composed of the cytokine receptor gp130, WSX-1 (IL-27 receptor alpha), and CNTFR (ciliary neurotrophic factor receptor), and has also been reported to act through formyl peptide receptor 2 (FPR2/FPRL1). Signaling through these receptors has been linked to activation of STAT3 and AMPK pathways. Humanin has also been shown to induce chaperone-mediated autophagy in a dose-dependent manner in cell studies. Its plasma half-life and pharmacokinetics in humans have not been established, since it has not undergone formal human pharmacokinetic study.

Potential benefits and research applications

Neuroprotection

What is being investigated: whether Humanin or its analogs can protect neurons from the kind of damage seen in Alzheimer’s disease, Huntington’s disease, and stroke. How the effect might occur: by blocking apoptotic signaling and amyloid-beta toxicity in neurons. Evidence: this is the original context in which Humanin was discovered, and has been shown in cell cultures and in rodent models of Alzheimer’s-like pathology and stroke, using the peptide or synthetic analogs such as HNG and HNGF6A. Strength: animal and laboratory evidence only; this has not been studied in human neurological patients. Limitation: rodent models of neurodegeneration do not reliably predict human clinical outcomes.

Metabolic and insulin-sensitivity effects

What is being investigated: a possible role for Humanin in glucose regulation and pancreatic beta-cell survival. How the effect might occur: by protecting insulin-producing beta cells from stress-induced death and by influencing insulin signaling pathways. Evidence: animal studies, including diabetic rodent models where Humanin analogs appeared to help normalize blood glucose, plus human observational studies correlating lower circulating Humanin levels with insulin resistance and metabolic disease. Strength: preliminary; the human data is associative (correlation) rather than interventional. Limitation: no human trial has tested whether administering Humanin changes glucose control in people.

Cardiovascular protection

What is being investigated: whether Humanin can reduce damage from myocardial ischemia-reperfusion injury (the damage that occurs when blood flow returns to heart tissue after a blockage) and slow atherosclerotic plaque development. How the effect might occur: through anti-apoptotic and anti-inflammatory action in vascular and cardiac tissue. Evidence: demonstrated in mouse models of cardiac ischemia-reperfusion injury, and Humanin has been found expressed in human vascular tissue in observational studies. Strength: animal and observational human data; no interventional human cardiovascular trial exists. Limitation: whether exogenous Humanin administration would replicate these protective effects in human cardiovascular disease has not been tested.

Lifespan and cellular stress resistance

What is being investigated: whether Humanin overexpression extends lifespan and improves stress resistance at the organismal level. How the effect might occur: through its broad anti-apoptotic and pro-survival signaling. Evidence: overexpression of Humanin has been shown to extend lifespan in Caenorhabditis elegans (a nematode model organism), and circulating Humanin levels have been observed to decline with age in some human cohort studies. Strength: invertebrate lifespan data plus human observational correlation only. Limitation: nematode lifespan extension does not establish a mammalian or human anti-aging effect, and correlation between low Humanin and aging does not prove that raising it would produce benefit.

What dosage information circulates?

Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Amounts studied in human research

No established or reliably sourced dosing information was identified. Humanin has not been administered to humans in a registered clinical trial as of this review; existing human data is limited to observational studies measuring naturally circulating Humanin levels in blood, which did not involve dosing the peptide at all.

Amounts studied in animal research

Rodent studies of Humanin and its analogs (particularly HNG) have used injected doses in the range of roughly 2 to 30 micrograms per injection, or on the order of a few micrograms per kilogram of body weight, given intraperitoneally in various neuroprotection and metabolic studies, though exact amounts vary considerably by study, species, analog used, and research objective, and figures are not standardized across the literature (Evidence category: Published animal research). Duration and frequency also vary widely by protocol, from single-dose challenge studies to repeated dosing over several weeks. No consistent, citable dose-response protocol has been established across studies.

Practitioner and community-reported protocols

Peptide vendor and longevity-community websites describe subcutaneous injection protocols for “Humanin” or “HNG,” commonly citing amounts in the range of roughly 0.5 to 2 milligrams per day or every other day, self-reconstituted from powder sold as a research chemical. These figures are widely repeated across peptide-vendor and dosing-guide websites, but none of the pages reviewed for this entry trace the numbers to a published study, a pharmacokinetic rationale, or an identifiable original source (evidence category: community/vendor reported; origin unclear). Widely repeated online, but its original source could not be verified. These products are typically sold labeled “not for human consumption” or “research use only,” and no clinical safety data exists for injecting Humanin peptide in people at any dose.

Side effects, risks, and limitations

Because Humanin has not been through human clinical trials, there is no formal human safety or side-effect profile. Animal studies have not reported serious adverse findings at the doses tested, but animal tolerability does not establish human safety. Peptides purchased from research-chemical vendors carry additional risks unrelated to the molecule itself: purity, sterility, correct identity, and accurate concentration are not guaranteed and are not independently verified in the way an approved pharmaceutical product would be. Self-injection of an unapproved, unregulated peptide carries risk of infection, incorrect dosing, and unknown long-term effects. Long-term human effects of chronically elevated Humanin signaling, including any effect on cancer cell survival (since anti-apoptotic signaling can theoretically protect abnormal cells as well as healthy ones), have not been studied and remain a mechanism-based concern rather than a confirmed risk.

Regulatory and developmental status

Humanin has no approved medical use anywhere and is not an FDA-approved or EMA-approved drug. It is not a registered dietary supplement ingredient. It is sold by research-chemical and peptide vendors labeled for laboratory or research use only, not for human consumption. No company has publicly disclosed an active human clinical trial program for Humanin or its analogs as of this review. It remains a preclinical research compound.

Frequently asked questions

What is Humanin?

Humanin is a small peptide made from a gene located inside mitochondrial DNA. It was discovered in 2001 and has been studied mainly in cell cultures and animals for its ability to protect cells from stress-induced death.

How does Humanin work?

It appears to interfere with the cell’s programmed self-destruct pathway (apoptosis) and to signal through cell-surface receptors including a gp130/WSX-1/CNTFR receptor complex, though the full picture of its biology is still being worked out in laboratory research.

What dosage has been studied in humans?

None. No established or reliably sourced dosing information was identified because Humanin has not been given to humans in a registered clinical trial.

What dosage information circulates online?

Peptide-vendor and dosing-guide websites describe self-injected amounts in the range of roughly 0.5 to 2 milligrams, but these figures are widely repeated online without an identifiable original source and are not supported by any published human study.

Has Humanin been studied in humans at all?

Only observationally. Researchers have measured naturally circulating Humanin levels in human blood and correlated them with age and metabolic health, but no study has administered Humanin to human subjects.

What is HNG?

HNG (Humanin-glycine) is a synthetic analog with a single amino-acid substitution reported to be substantially more potent than natural Humanin in laboratory assays. It has been used in many of the animal studies cited for Humanin’s effects and is also sold under vendor and community peptide listings.

Is Humanin approved for any medical use?

No. It has no approved indication anywhere and is not a recognized dietary supplement ingredient.

What remains unknown?

Whether Humanin administration produces any of its proposed benefits in humans, what a safe or effective human dose would be, its human pharmacokinetics, and its long-term safety are all unknown because the compound has not been through human clinical testing.

Bottom line

Humanin is a genuinely interesting mitochondrial signaling peptide with a substantial body of laboratory and animal evidence supporting a role in cell survival, stress resistance, and possibly metabolic and neurological health. None of that evidence has been confirmed in human clinical trials, and no dosage for human use has ever been established in published research. Amounts circulating on peptide-vendor and community websites are not traceable to any study and should not be mistaken for a validated protocol. Humanin remains an early-stage research compound, not an approved or clinically tested therapeutic.